Induction of antigen-specific tumor immunity by genetic and cellular vaccines against MAGE: Enhanced tumor protection by coexpression of granulocyte-macrophage colony stimulating factor and B7-1

Molecular Medicine

Volumn 2, Issue 5, 1996, Pages 545-555

  Büeler, Hansruedi ^a   Mulligan, Richard C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TUMOR MARKER; VACCINE;

ANIMAL CELL; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; CYTOTOXIC T LYMPHOCYTE; GENE INDUCTION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROTECTION; TUMOR IMMUNITY;

EID: 0029844184     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03401639     Document Type: Article

References (57)

1. Bakker AB, Schreurs MW, de Boer AJ, et al. (1994). Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J. Exp. Med. 179: 1005-1009.
2. Boel P, Wildmann C, Sensi ML, et al. (1995). BAGE: A new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 2: 167-175.
3. Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A. (1994). Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 12: 337-365.
4. Brichard V, Van Pel A, Wolfel T, et al. (1993). The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 178: 489-495.
5. + cytotoxic T lymphocytes. J. Exp. Med. 181: 363-368.
6. Cox AL, Skipper J, Chen Y, et al. (1994). Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264: 716-719.
7. Gaugler B, Van den Eynde B, van der Bruggen P, et al. (1994). Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J. Exp. Med. 179: 921-930.
8. Kawakami Y, Eliyahu S, Delgado CH, et al. (1994). Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. U.S.A. 91: 3515-3519.
9. Van den Eynde B, Peeters O, De Backer O, Gaugler B, Lucas S, Boon T. (1995). A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J. Exp. Med. 182: 689-698.
10. van der Bruggen P, Traversari C, Chomez P, et al. (1991). A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254: 1643-1647.
11. De Plaen E, Arden K, Traversari C, et al. (1994). Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics 40: 360-369.
12. Muscatelli F, Walker AP, De Plaen E, Stafford AN, Monaco AP. (1995). Isolation and characterization of a MAGE gene family in the Xp21.3 region. Proc. Natl. Acad. Sci. U.S.A. 92: 4987-4991.
13. Patard JJ, Brasseur F, Gil-Diez S, et al. (1995). Expression of MAGE genes in transitional-cell carcinomas of the urinary bladder. Int. J. Cancer 64: 60-64.
14. Russo V, Traversari C, Verrecchia A, Mottolese M, Natali PG, Bordignon C. (1995). Expression of the MAGE gene family in primary and metastatic human breast cancer: Implications for tumor antigen-specific immunotherapy. Int. J. Cancer 64: 216-221.
15. Takahashi K, Shichijo S, Noguchi M, Hirohata M, Itoh K. (1995). Identification of MAGE-1 and MAGE-4 proteins in spermatogonia and primary spermatocytes of testis. Cancer Res. 55: 3478-3482.
16. Amar-Costesec A, Godelaine D, Stockert E, van der Bruggen P, Beaufay H, Chen YT. (1994). The tumor protein MAGE-1 is located in the cytosol of human melanoma cells. Biochem. Biophys. Res. Commun. 204: 710-715.
17. Kocher T, Schultz-Thater E, Gudat F, et al. (1995). Identification and intracellular location of MAGE-3 gene product. Cancer Res. 55: 2236-2239.
18. Schultz-Thater E, Juretic A, Dellabona P, et al. (1994). MAGE-1 gene product is a cytoplasmic protein. Int. J. Cancer 59: 435-439.
19. Traversari C, van der Bruggen P, Luescher IF, et al. (1992). A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J. Exp. Med. 176: 1453-1457.
20. van der Bruggen P, Bastin J, Gajewski T, et al. (1994). A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur. J. Immunol. 24: 3038-3043.
21. van der Bruggen P, Szikora JP, Boel P, et al. (1994). Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw * 1601. Eur. J. Immunol. 24: 2134-2140.
22. Hoon DS, Yuzuki D, Hayashida M, Morton DL. (1995). Melanoma patients immunized with melanoma cell vaccine induce antibody responses to recombinant MAGE-1 antigen. J. Immunol. 154: 730-737.
23. Mukherji B, Chakraborty NG, Yamasaki S, et al. (1995). Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc. Natl. Acad. Sci. U.S.A. 92: 8078-8082.
24. Salgaller ML, Weber JS, Koenig S, Yannelli JR, Rosenberg SA. (1994). Generation of specific anti-melanoma reactivity by stimulation of human tumor-infiltrating lymphocytes with MAGE-1 synthetic peptide. Cancer Immunol. Immunother. 39: 105-116.
25. Dranoff G, Jaffee E, Lazenby A, et al. (1993). Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-slimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. U.S.A. 90: 3539-3543.
26. Riviere I, Brose K, Mulligan RC. (1995). Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. Proc. Natl. Acad. Sci. U.S.A. 92: 6733-6737.
27. Miller AD. (1990). Retrovirus packaging cells. Hum. Gene Ther. 1: 5-14.
28. Danos O, Mulligan RC. (1988). Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. Proc. Natl. Acad. Sci. U.S.A. 85: 6460-6464.
29. + cells but markedly decreased helper cell activity in mice lacking CD4. Nature 353: 180-184.
30. Fung-Leung WP, Schilham MW, Rahemtulla A, et al. (1991). CD8 is needed for development of cytotoxic T cells but not helper T cells. Cell 65: 443-449.
31. Tang DC, De Vit M, Johnston SA. (1992). Genetic immunization is a simple method for eliciting an immune response. Nature 356: 152-154.
32. Ulmer JB, Donnelly JJ, Parker SE, et al. (1993). Heterologous protection against influenza by injection of DNA encoding a viral protein [see comments]. Science 259: 1745-1749.
33. Conry RM, Lo Buglio AF, Loechel F, et al. (1995). A carcinoembryonic antigen polynucleotide vaccine has in vivo antitumor activity. Gene Ther. 2: 59-65.
34. Wang B, Merva M, Dang K, Ugen KE, Williams WV, Weiner DB. (1995). Immunization by direct DNA inoculation indtices rejection of tumor cell challenge. Hum. Gene Ther. 6: 407-418.
35. Major ME, Vitvitski L, Mink MA, et al. (1995). DNA-based immunization with chimeric vectors for the induction of immune responses against the hepatitis C virus nucleocapsid. J. Virol. 69: 5798-5805.
36. Levitsky HI, Lazenby A, Hayashi RJ, Pardoll DM. (1994). In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression. J. Hxp. Med. 179: 1215-1224.
37. Inaba K, Inaba M, Romani N, et al. (1992). Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 176: 1693-1702.
38. Guery JC, Adorini L. (1995). Dendritic cells are the most efficient in presenting endogenous naturally processed self-epitopes to class II-restricted T cells. J. Immunol. 154: 536-544.
39. Steinman RM. (1991). The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 9: 271-296.
40. Allison JP. (1994). CD28-B7 interactions in T-cell activation. Curr. Opin. Immunol. 6: 414-419.
41. Boon T, Coulie P, Marchand M, Weynants P, Wolfel T, Brichard V. (1994). Genes coding for tumor rejection antigens: perspectives for specific immunotherapy. In: DeVita VT, Hellmann S, Rosenberg SA (eds). Important Advances in Oncology. J.B. Lippincott Company: Philadelphia, pp. 53-69.
42. Repique CJ, Kettering JD, Gridley DS. (1992). Immunosuppression derived from human B-lymphoblastoid and melanoma cell lines. Cancer Invest. 10: 201-208.
43. Young MR, Wright MA, Coogan M, Young ME, Bagash J. (1992). Tumor-derived cytokines induce bone marrow suppressor cells that mediate immunosuppression through transforming growth factor beta. Cancer Immunol. Immunother. 35: 14-18.
44. Kuppner MC, Hamou MF, Bodmer S, Fontana A, de Tribolet N. (1988). The glioblastoma-derived T-cell suppressor factor/transforming growth factor beta 2 inhibits the generation of lymphokine-activated killer (LAK) cells. Int. J. Cancer 42: 562-567.
45. Mizoguchi H, O'Shea JJ, Longo DL, Loeffler CM, McVicar DW, Ochoa AC. (1992). Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice [see comments]. Science 258: 1795-1798.
46. Xiang Z, Ertl HC. (1995). Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. Immunity 2: 129-135.
47. Baskar S, Ostrand-Rosenberg S, Nabavi N, Nadler LM, Freeman GJ, Glimcher LH. (1993). Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. Proc. Natl. Acad. Sci. U.S.A. 90: 5687-5690.
48. + T cells by B7-transfected melanoma cells. Science 259: 368-370.
49. Hodge JW, McLaughlin JP, Abrams SI, Shupert WL, Schlom J, Kantor JA. (1995). Admixture of a recombinant vaccinia virus containing the gene for the costimulatory molecule B7 and a recombinant vaccinia virus containing a tumor-associated antigen gene results in enhanced specific T-cell responses and antitumor immunity. Cancer Res. 55: 3598-3603.
50. Kuchroo VK, Das MP, Brown JA, et al. (1995). B7-1 and B7-2 costimulatory molecules activate differentially the Thl/Th2 developmental pathways: application to autoimmune disease therapy. Cell 80: 707-718.
51. + T cells. Annu. Rev. Immunol. 12: 635-673.
52. Wu TC, Huang AY, Jaffee EM, Levitsky HI, Pardoll DM. (1995). A reassessment of the role of B7-1 expression in tumor rejection. J. Exp. Med. 182: 1415-1421.
53. Huang AY, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H. (1994). Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264: 961-965.
54. Pardoll DM. (1994). Tumour antigens. A new look for the 1990s [news; comment]. Nature 369: 357.
55. zur Hausen H, and de Villiers EM. (1994). Human papillomaviruses. Annu. Rev. Microbiol. 48: 427-447.
56. Rubin SC, Finstad CL, Federici MG, Scheiner L, Lloyd KO, Hoskins WJ. (1994). Prevalence and significance of HER-2/neu expression in early epithelial ovarian cancer. Cancer 73: 1456-1459.
57. el-Shirbiny AM. (1994). Prostatic specific antigen. Adv. Clin. Chem. 31: 99-133.